搜尋結果
2024年5月6日 · Continued development and commercial preparation for a 2024 season variant-adapted COVID-19 vaccine. First quarter 2024 revenues of €187.6 million, net loss of €315.1 million and loss per share of €1.31 ($1.421) Maintained strong financial position with €16.9 billion in cash, cash equivalents and security investments.
2024年5月6日 · BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases.
2 天前 · Hours. 15. Minutes. 18. Seconds. 53. -40% on all our subscriptions* Exceptional extension! Take advantage of the offer. * See conditions on site. Financials. More Fundamentals * Assessed data. Chart BioNTech SE. Duration. Period. Style. Dynamic Chart.
- (17)
- BIONTECH SE
Summary. Quotes. Charts. News. Ratings. Calendar. Company. Financials. Consensus. Revisions. Funds and ETFs. Business Summary. BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases.
- (16)
- BIONTECH SE
2 天前 · Financials BioNTech SE. BioNTech SE: Forcasts, revenue, earnings, analysts expectations, ratios for BioNTech SE Stock | BNTX | US09075V1026.
2023年11月6日 · Stock Market. Equities. BNTX Stock. News BioNTech SE. BioNTech SE agreed to acquire Aexerna Therapeutics. BioNTech SE agreed to acquire Aexerna Therapeutics on November 7, 2023....
2023年1月6日 · MAINZ, Germany, January 6, 2023 – BioNTech SE (Nasdaq: BNTX, “BioNTech”, “the Company”) today announced that the Company signed a Memorandum of Understanding (“MoU”) with the Government of the United Kingdom (“UK”) to benefit patients by accelerating clinical trials for personalized mRNA immunotherapies with the aim to provide personalized cance...
